Fresh from the biotech pipeline: fewer approvals, but biologics gain share.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36624153.
- Also identified by DOI 10.1038/s41587-022-01630-6 and PMC identifier 9838261.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
2022 saw a 25% drop in new drug approvals and a less predictable regulator.
Medical subject headings
- Biological Products